Last updated 8 days ago
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
150 patients around the world
Available in United States, Brazil
Eli Lilly and Company
7Research sites
150Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 1
Requirements for the patient
To 35 Years
All Gender
Medical requirements
- Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, and one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening.Have Stage 1b or Stage 2 type 1 diabetes.Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening.
- Have any other type of diabetes.Have uncontrolled high blood pressure.Have had a heart attack, heart disease, stroke, or heart failure.Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy.Have a current or recent clinically serious infection.
Sites
IPEC - Instituto de Pesquisa Clínica
Centro de Diabetes Curitiba - Curitiba, Parana
Hospital Universitário Walter Cantídio - Universidade Federal do Ceará - Fortaleza, Ceara
Freire Pesquisa Clínica
CPClin – Centro de Pesquisas Clinicas LTDA
Hospital das Clínicas da FMUSP - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP
Universidade Federal do Rio de Janeiro - Faculdade de Medicina - UFRJ
StudyBARICADE-DELAY
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Diabetes mellitus type 1
Requirements
To 35 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07222137
